Rheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.
Study Type
OBSERVATIONAL
Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
Faculty of Medicine
Shibīn al Kawm, Egypt
The risk of COVID-19 infection among RA patients
Realtion between hydroxychloroquine use and COVID-19 infection
Time frame: 12 week
The incidence of hospitalization for Covid-19 patients.
Number of cases and number of hospitalization days
Time frame: 12 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.